The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: A PRISMA-compliant systematic review and meta-analysis

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the primary treatment in treating with EGFR mutant nonsmall cell lung cancer (NSCLC). This systematic review and meta-analysis aimed to evaluate the efficacy and safety of the third-generation EGFR-TKI, osimertinib,...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jing, Li, Xuemei, Shao, Yinghong, Guo, Xiyun, He, Jinggui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
6700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447427/
https://www.ncbi.nlm.nih.gov/pubmed/32846826
http://dx.doi.org/10.1097/MD.0000000000021826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447427/
https://www.ncbi.nlm.nih.gov/pubmed/32846826
http://dx.doi.org/10.1097/MD.0000000000021826

Ejemplares similares